

Global Primary Sclerosing Cholangitis Treatment Market Growth (Status and Outlook) 2022-2028

<https://marketpublishers.com/r/GA5026FD127EEN.html>

Date: January 2021

Pages: 124

Price: US\$ 3,660.00 (Single User License)

ID: GA5026FD127EEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Primary Sclerosing Cholangitis Treatment will have significant change from previous year. According to our (LP Information) latest study, the global Primary Sclerosing Cholangitis Treatment market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Primary Sclerosing Cholangitis Treatment market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Primary Sclerosing Cholangitis Treatment market is expected at value of US\$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Primary Sclerosing Cholangitis Treatment market, reaching US\$ million by the year 2028. As for the Europe Primary Sclerosing Cholangitis Treatment landscape, Germany is projected to reach US\$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Primary Sclerosing Cholangitis Treatment players cover Allergan, Glenmark, Impax Laboratories, and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Sclerosing Cholangitis Treatment market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

Liver Transplantation Operation

UDCA Drugs

PSC Drugs

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

Hospital

Clinics

Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

Allergan

Glenmark

Impax Laboratories

Mylan

Teva Pharmaceuticals

Dr. Falk Pharma

Daewoong Pharmaceutical

Epic Pharma

Mitsubishi Tanabe Pharma

Lannett

Bruschettini

Shanghai Pharma

Grindeks

Acorda Therapeutics

Gilead Sciences

Intercept Pharmaceuticals

Shire Plc

NGM Biopharmaceuticals

Conatus Pharmaceuticals

Durect Corporation

Sirnaomics

Shenzhen HighTide Biopharmaceuticals

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Primary Sclerosing Cholangitis Treatment Market Size 2017-2028
 - 2.1.2 Primary Sclerosing Cholangitis Treatment Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Primary Sclerosing Cholangitis Treatment Segment by Type
 - 2.2.1 Liver Transplantation Operation
 - 2.2.2 UDCA Drugs
 - 2.2.3 PSC Drugs
- 2.3 Primary Sclerosing Cholangitis Treatment Market Size by Type
 - 2.3.1 Primary Sclerosing Cholangitis Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028)
 - 2.3.2 Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)
- 2.4 Primary Sclerosing Cholangitis Treatment Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinics
 - 2.4.3 Other
- 2.5 Primary Sclerosing Cholangitis Treatment Market Size by Application
 - 2.5.1 Primary Sclerosing Cholangitis Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028)
 - 2.5.2 Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)

3 PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET SIZE BY PLAYER

3.1 Primary Sclerosing Cholangitis Treatment Market Size Market Share by Players

3.1.1 Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2020-2022)

3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2020-2022)

3.2 Global Primary Sclerosing Cholangitis Treatment Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 PRIMARY SCLEROSING CHOLANGITIS TREATMENT BY REGIONS

4.1 Primary Sclerosing Cholangitis Treatment Market Size by Regions (2017-2022)

4.2 Americas Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)

4.3 APAC Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)

4.4 Europe Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)

4.5 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Growth (2017-2022)

5 AMERICAS

5.1 Americas Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)

5.2 Americas Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)

5.3 Americas Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Primary Sclerosing Cholangitis Treatment Market Size by Region
(2017-2022)

6.2 APAC Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)

6.3 APAC Primary Sclerosing Cholangitis Treatment Market Size by Application
(2017-2022)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Primary Sclerosing Cholangitis Treatment by Country (2017-2022)

7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)

7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application
(2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment by Region
(2017-2022)

8.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type
(2017-2022)

8.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by
Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET FORECAST

- 10.1 Global Primary Sclerosing Cholangitis Treatment Forecast by Regions (2023-2028)
 - 10.1.1 Global Primary Sclerosing Cholangitis Treatment Forecast by Regions (2023-2028)
 - 10.1.2 Americas Primary Sclerosing Cholangitis Treatment Forecast
 - 10.1.3 APAC Primary Sclerosing Cholangitis Treatment Forecast
 - 10.1.4 Europe Primary Sclerosing Cholangitis Treatment Forecast
 - 10.1.5 Middle East & Africa Primary Sclerosing Cholangitis Treatment Forecast
- 10.2 Americas Primary Sclerosing Cholangitis Treatment Forecast by Country (2023-2028)
 - 10.2.1 United States Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.2.2 Canada Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.2.3 Mexico Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.2.4 Brazil Primary Sclerosing Cholangitis Treatment Market Forecast
- 10.3 APAC Primary Sclerosing Cholangitis Treatment Forecast by Region (2023-2028)
 - 10.3.1 China Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.3.2 Japan Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.3.3 Korea Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.3.4 Southeast Asia Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.3.5 India Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.3.6 Australia Primary Sclerosing Cholangitis Treatment Market Forecast
- 10.4 Europe Primary Sclerosing Cholangitis Treatment Forecast by Country (2023-2028)
 - 10.4.1 Germany Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.4.2 France Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.4.3 UK Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.4.4 Italy Primary Sclerosing Cholangitis Treatment Market Forecast
 - 10.4.5 Russia Primary Sclerosing Cholangitis Treatment Market Forecast
- 10.5 Middle East & Africa Primary Sclerosing Cholangitis Treatment Forecast by Region (2023-2028)
 - 10.5.1 Egypt Primary Sclerosing Cholangitis Treatment Market Forecast

- 10.5.2 South Africa Primary Sclerosing Cholangitis Treatment Market Forecast
- 10.5.3 Israel Primary Sclerosing Cholangitis Treatment Market Forecast
- 10.5.4 Turkey Primary Sclerosing Cholangitis Treatment Market Forecast
- 10.5.5 GCC Countries Primary Sclerosing Cholangitis Treatment Market Forecast
- 10.6 Global Primary Sclerosing Cholangitis Treatment Forecast by Type (2023-2028)
- 10.7 Global Primary Sclerosing Cholangitis Treatment Forecast by Application (2023-2028)

11 KEY PLAYERS ANALYSIS

11.1 Allergan

- 11.1.1 Allergan Company Information
- 11.1.2 Allergan Primary Sclerosing Cholangitis Treatment Product Offered
- 11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Allergan Main Business Overview
- 11.1.5 Allergan Latest Developments

11.2 Glenmark

- 11.2.1 Glenmark Company Information
- 11.2.2 Glenmark Primary Sclerosing Cholangitis Treatment Product Offered
- 11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 Glenmark Main Business Overview
- 11.2.5 Glenmark Latest Developments

11.3 Impax Laboratories

- 11.3.1 Impax Laboratories Company Information
- 11.3.2 Impax Laboratories Primary Sclerosing Cholangitis Treatment Product Offered
- 11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Impax Laboratories Main Business Overview
- 11.3.5 Impax Laboratories Latest Developments

11.4 Mylan

- 11.4.1 Mylan Company Information
- 11.4.2 Mylan Primary Sclerosing Cholangitis Treatment Product Offered
- 11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 Mylan Main Business Overview
- 11.4.5 Mylan Latest Developments

11.5 Teva Pharmaceuticals

- 11.5.1 Teva Pharmaceuticals Company Information
- 11.5.2 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
- 11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 Teva Pharmaceuticals Main Business Overview
- 11.5.5 Teva Pharmaceuticals Latest Developments
- 11.6 Dr. Falk Pharma
 - 11.6.1 Dr. Falk Pharma Company Information
 - 11.6.2 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.6.4 Dr. Falk Pharma Main Business Overview
 - 11.6.5 Dr. Falk Pharma Latest Developments
- 11.7 Daewoong Pharmaceutical
 - 11.7.1 Daewoong Pharmaceutical Company Information
 - 11.7.2 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.7.4 Daewoong Pharmaceutical Main Business Overview
 - 11.7.5 Daewoong Pharmaceutical Latest Developments
- 11.8 Epic Pharma
 - 11.8.1 Epic Pharma Company Information
 - 11.8.2 Epic Pharma Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.8.4 Epic Pharma Main Business Overview
 - 11.8.5 Epic Pharma Latest Developments
- 11.9 Mitsubishi Tanabe Pharma
 - 11.9.1 Mitsubishi Tanabe Pharma Company Information
 - 11.9.2 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.9.4 Mitsubishi Tanabe Pharma Main Business Overview
 - 11.9.5 Mitsubishi Tanabe Pharma Latest Developments
- 11.10 Lannett
 - 11.10.1 Lannett Company Information

- 11.10.2 Lannett Primary Sclerosing Cholangitis Treatment Product Offered
- 11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
- 11.10.4 Lannett Main Business Overview
- 11.10.5 Lannett Latest Developments
- 11.11 Bruschetti
 - 11.11.1 Bruschetti Company Information
 - 11.11.2 Bruschetti Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.11.3 Bruschetti Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.11.4 Bruschetti Main Business Overview
 - 11.11.5 Bruschetti Latest Developments
- 11.12 Shanghai Pharma
 - 11.12.1 Shanghai Pharma Company Information
 - 11.12.2 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.12.4 Shanghai Pharma Main Business Overview
 - 11.12.5 Shanghai Pharma Latest Developments
- 11.13 Grindeks
 - 11.13.1 Grindeks Company Information
 - 11.13.2 Grindeks Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.13.4 Grindeks Main Business Overview
 - 11.13.5 Grindeks Latest Developments
- 11.14 Acorda Therapeutics
 - 11.14.1 Acorda Therapeutics Company Information
 - 11.14.2 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.14.4 Acorda Therapeutics Main Business Overview
 - 11.14.5 Acorda Therapeutics Latest Developments
- 11.15 Gilead Sciences
 - 11.15.1 Gilead Sciences Company Information
 - 11.15.2 Gilead Sciences Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)

- 11.15.4 Gilead Sciences Main Business Overview
- 11.15.5 Gilead Sciences Latest Developments
- 11.16 Intercept Pharmaceuticals
 - 11.16.1 Intercept Pharmaceuticals Company Information
 - 11.16.2 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.16.4 Intercept Pharmaceuticals Main Business Overview
 - 11.16.5 Intercept Pharmaceuticals Latest Developments
- 11.17 Shire Plc
 - 11.17.1 Shire Plc Company Information
 - 11.17.2 Shire Plc Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.17.4 Shire Plc Main Business Overview
 - 11.17.5 Shire Plc Latest Developments
- 11.18 NGM Biopharmaceuticals
 - 11.18.1 NGM Biopharmaceuticals Company Information
 - 11.18.2 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.18.4 NGM Biopharmaceuticals Main Business Overview
 - 11.18.5 NGM Biopharmaceuticals Latest Developments
- 11.19 Conatus Pharmaceuticals
 - 11.19.1 Conatus Pharmaceuticals Company Information
 - 11.19.2 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.19.4 Conatus Pharmaceuticals Main Business Overview
 - 11.19.5 Conatus Pharmaceuticals Latest Developments
- 11.20 Durect Corporation
 - 11.20.1 Durect Corporation Company Information
 - 11.20.2 Durect Corporation Primary Sclerosing Cholangitis Treatment Product Offered
 - 11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)
 - 11.20.4 Durect Corporation Main Business Overview

11.20.5 Durect Corporation Latest Developments

11.21 Sirnaomics

11.21.1 Sirnaomics Company Information

11.21.2 Sirnaomics Primary Sclerosing Cholangitis Treatment Product Offered

11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.21.4 Sirnaomics Main Business Overview

11.21.5 Sirnaomics Latest Developments

11.22 Shenzhen HighTide Biopharmaceuticals

11.22.1 Shenzhen HighTide Biopharmaceuticals Company Information

11.22.2 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered

11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue, Gross Margin and Market Share (2020-2022)

11.22.4 Shenzhen HighTide Biopharmaceuticals Main Business Overview

11.22.5 Shenzhen HighTide Biopharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Primary Sclerosing Cholangitis Treatment Market Size CAGR by Region (2017 VS 2022 VS 2028) & (\$ Millions)

Table 2. Major Players of Liver Transplantation Operation

Table 3. Major Players of UDCA Drugs

Table 4. Major Players of PSC Drugs

Table 5. Primary Sclerosing Cholangitis Treatment Market Size CAGR by Type (2017 VS 2022 VS 2028) & (\$ Millions)

Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (\$ Millions)

Table 7. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)

Table 8. Primary Sclerosing Cholangitis Treatment Market Size CAGR by Application (2017 VS 2022 VS 2028) & (\$ Millions)

Table 9. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (\$ Millions)

Table 10. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)

Table 11. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2020-2022) & (\$ Millions)

Table 12. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Player (2020-2022)

Table 13. Primary Sclerosing Cholangitis Treatment Key Players Head office and Products Offered

Table 14. Primary Sclerosing Cholangitis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Primary Sclerosing Cholangitis Treatment Market Size by Regions 2017-2022 & (\$ Millions)

Table 18. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Regions (2017-2022)

Table 19. Americas Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (\$ Millions)

Table 20. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Country (2017-2022)

Table 21. Americas Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (\$ Millions)

Table 22. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)

Table 23. Americas Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (\$ Millions)

Table 24. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)

Table 25. APAC Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (\$ Millions)

Table 26. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region (2017-2022)

Table 27. APAC Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (\$ Millions)

Table 28. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)

Table 29. APAC Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (\$ Millions)

Table 30. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)

Table 31. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (\$ Millions)

Table 32. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Country (2017-2022)

Table 33. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (\$ Millions)

Table 34. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2022)

Table 35. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (\$ Millions)

Table 36. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)

Table 37. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (\$ Millions)

Table 38. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region (2017-2022)

Table 39. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (\$ Millions)

Table 40. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size

Market Share by Type (2017-2022)

Table 41. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (\$ Millions)

Table 42. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2022)

Table 43. Key Market Drivers & Growth Opportunities of Primary Sclerosing Cholangitis Treatment

Table 44. Key Market Challenges & Risks of Primary Sclerosing Cholangitis Treatment

Table 45. Key Industry Trends of Primary Sclerosing Cholangitis Treatment

Table 46. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Regions (2023-2028) & (\$ Millions)

Table 47. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share Forecast by Regions (2023-2028)

Table 48. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Type (2023-2028) & (\$ Millions)

Table 49. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share Forecast by Type (2023-2028)

Table 50. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Application (2023-2028) & (\$ Millions)

Table 51. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share Forecast by Application (2023-2028)

Table 52. Allergan Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 53. Allergan Primary Sclerosing Cholangitis Treatment Product Offered

Table 54. Allergan Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 55. Allergan Main Business

Table 56. Allergan Latest Developments

Table 57. Glenmark Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 58. Glenmark Primary Sclerosing Cholangitis Treatment Product Offered

Table 59. Glenmark Main Business

Table 60. Glenmark Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 61. Glenmark Latest Developments

Table 62. Impax Laboratories Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 63. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product Offered

Table 64. Impax Laboratories Main Business

Table 65. Impax Laboratories Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 66. Impax Laboratories Latest Developments

Table 67. Mylan Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 68. Mylan Primary Sclerosing Cholangitis Treatment Product Offered

Table 69. Mylan Main Business

Table 70. Mylan Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 71. Mylan Latest Developments

Table 72. Teva Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 73. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered

Table 74. Teva Pharmaceuticals Main Business

Table 75. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 76. Teva Pharmaceuticals Latest Developments

Table 77. Dr. Falk Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 78. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product Offered

Table 79. Dr. Falk Pharma Main Business

Table 80. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 81. Dr. Falk Pharma Latest Developments

Table 82. Daewoong Pharmaceutical Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 83. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product Offered

Table 84. Daewoong Pharmaceutical Main Business

Table 85. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 86. Daewoong Pharmaceutical Latest Developments

Table 87. Epic Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 88. Epic Pharma Primary Sclerosing Cholangitis Treatment Product Offered

Table 89. Epic Pharma Main Business

Table 90. Epic Pharma Primary Sclerosing Cholangitis Treatment Revenue (\$ million),

Gross Margin and Market Share (2020-2022)

Table 91. Epic Pharma Latest Developments

Table 92. Mitsubishi Tanabe Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 93. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product Offered

Table 94. Mitsubishi Tanabe Pharma Main Business

Table 95. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 96. Mitsubishi Tanabe Pharma Latest Developments

Table 97. Lannett Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 98. Lannett Primary Sclerosing Cholangitis Treatment Product Offered

Table 99. Lannett Main Business

Table 100. Lannett Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 101. Lannett Latest Developments

Table 102. Bruschettini Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 103. Bruschettini Primary Sclerosing Cholangitis Treatment Product Offered

Table 104. Bruschettini Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 105. Bruschettini Main Business

Table 106. Bruschettini Latest Developments

Table 107. Shanghai Pharma Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 108. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product Offered

Table 109. Shanghai Pharma Main Business

Table 110. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 111. Shanghai Pharma Latest Developments

Table 112. Grindeks Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 113. Grindeks Primary Sclerosing Cholangitis Treatment Product Offered

Table 114. Grindeks Main Business

Table 115. Grindeks Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 116. Grindeks Latest Developments

- Table 117. Acorda Therapeutics Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
- Table 118. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product Offered
- Table 119. Acorda Therapeutics Main Business
- Table 120. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)
- Table 121. Acorda Therapeutics Latest Developments
- Table 122. Gilead Sciences Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
- Table 123. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product Offered
- Table 124. Gilead Sciences Main Business
- Table 125. Gilead Sciences Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)
- Table 126. Gilead Sciences Latest Developments
- Table 127. Intercept Pharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
- Table 128. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
- Table 129. Intercept Pharmaceuticals Main Business
- Table 130. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)
- Table 131. Intercept Pharmaceuticals Latest Developments
- Table 132. Shire Plc Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
- Table 133. Shire Plc Primary Sclerosing Cholangitis Treatment Product Offered
- Table 134. Shire Plc Main Business
- Table 135. Shire Plc Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)
- Table 136. Shire Plc Latest Developments
- Table 137. NGM Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors
- Table 138. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered
- Table 139. NGM Biopharmaceuticals Main Business
- Table 140. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)
- Table 141. NGM Biopharmaceuticals Latest Developments
- Table 142. Conatus Pharmaceuticals Details, Company Type, Primary Sclerosing

Cholangitis Treatment Area Served and Its Competitors

Table 143. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered

Table 144. Conatus Pharmaceuticals Main Business

Table 145. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 146. Conatus Pharmaceuticals Latest Developments

Table 147. Durect Corporation Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 148. Durect Corporation Primary Sclerosing Cholangitis Treatment Product Offered

Table 149. Durect Corporation Main Business

Table 150. Durect Corporation Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 151. Durect Corporation Latest Developments

Table 152. Sirnaomics Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 153. Sirnaomics Primary Sclerosing Cholangitis Treatment Product Offered

Table 154. Sirnaomics Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 155. Sirnaomics Main Business

Table 156. Sirnaomics Latest Developments

Table 157. Shenzhen HighTide Biopharmaceuticals Details, Company Type, Primary Sclerosing Cholangitis Treatment Area Served and Its Competitors

Table 158. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Offered

Table 159. Shenzhen HighTide Biopharmaceuticals Main Business

Table 160. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Revenue (\$ million), Gross Margin and Market Share (2020-2022)

Table 161. Shenzhen HighTide Biopharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Primary Sclerosing Cholangitis Treatment Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (\$ Millions)
- Figure 6. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type in 2021
- Figure 7. Primary Sclerosing Cholangitis Treatment in Hospital
- Figure 8. Global Primary Sclerosing Cholangitis Treatment Market: Hospital (2017-2022) & (\$ Millions)
- Figure 9. Primary Sclerosing Cholangitis Treatment in Clinics
- Figure 10. Global Primary Sclerosing Cholangitis Treatment Market: Clinics (2017-2022) & (\$ Millions)
- Figure 11. Primary Sclerosing Cholangitis Treatment in Other
- Figure 12. Global Primary Sclerosing Cholangitis Treatment Market: Other (2017-2022) & (\$ Millions)
- Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021
- Figure 14. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Player in 2021
- Figure 15. Global Primary Sclerosing Cholangitis Treatment Market Size Market Share by Regions (2017-2022)
- Figure 16. Americas Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 (\$ Millions)
- Figure 17. APAC Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 (\$ Millions)
- Figure 18. Europe Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 (\$ Millions)
- Figure 19. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size 2017-2022 (\$ Millions)
- Figure 20. Americas Primary Sclerosing Cholangitis Treatment Value Market Share by Country in 2021
- Figure 21. Americas Primary Sclerosing Cholangitis Treatment Consumption Market Share by Type in 2021

Figure 22. Americas Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021

Figure 23. United States Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 24. Canada Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 25. Mexico Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 26. Brazil Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 27. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region in 2021

Figure 28. APAC Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021

Figure 29. China Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 30. Japan Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 31. Korea Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 32. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 33. India Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 34. Australia Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 35. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Country in 2021

Figure 36. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type in 2021

Figure 37. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021

Figure 38. Germany Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 39. France Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 40. UK Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 41. Italy Primary Sclerosing Cholangitis Treatment Market Size Growth

2017-2022 (\$ Millions)

Figure 42. Russia Primary Sclerosing Cholangitis Treatment Market Size Growth

2017-2022 (\$ Millions)

Figure 43. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Region in 2021

Figure 44. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type in 2021

Figure 45. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application in 2021

Figure 46. Egypt Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 47. South Africa Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 48. Israel Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 49. Turkey Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 50. GCC Country Primary Sclerosing Cholangitis Treatment Market Size Growth 2017-2022 (\$ Millions)

Figure 51. Americas Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 52. APAC Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 53. Europe Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 54. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 55. United States Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 56. Canada Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 57. Mexico Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 58. Brazil Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 59. China Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 60. Japan Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 61. Korea Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 62. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 63. India Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 64. Australia Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 65. Germany Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 66. France Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 67. UK Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 68. Italy Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 69. Russia Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 70. Spain Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 71. Egypt Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 72. South Africa Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 73. Israel Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 74. Turkey Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

Figure 75. GCC Countries Primary Sclerosing Cholangitis Treatment Market Size 2023-2028 (\$ Millions)

I would like to order

Product name: Global Primary Sclerosing Cholangitis Treatment Market Growth (Status and Outlook) 2022-2028

Product link: <https://marketpublishers.com/r/GA5026FD127EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA5026FD127EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

